Report Detail

Pharma & Healthcare Dynamics in Post-pandemic Global Prophylactic HIV Drug Industry: Supply and Demand, Markets and Prices 2021-2027

  • RnM4318992
  • |
  • 27 May, 2021
  • |
  • Global
  • |
  • 131 Pages
  • |
  • GRD Survey
  • |
  • Pharma & Healthcare

Table of Contents

    1 Product Introduction and Overview

    • 1.1 Product Definition
    • 1.2 Product Specification
    • 1.3 Global Market Overview
      • 1.3.1 Global Prophylactic HIV Drug Market Status and Forecast (2016-2027)
      • 1.3.2 Global Prophylactic HIV Drug Sales Value CAGR by Region
    • 1.4 Market Drivers, Inhibitors
      • 1.4.1 Market Drivers
      • 1.4.2 Market Inhibitors
      • 1.4.3 COVID-19 Impact Analysis

    2 Global Prophylactic HIV Drug Supply by Company

    • 2.1 Global Prophylactic HIV Drug Sales Volume by Company
    • 2.2 Global Prophylactic HIV Drug Sales Value by Company
    • 2.3 Global Prophylactic HIV Drug Price by Company
    • 2.4 Prophylactic HIV Drug Production Location and Sales Area of Main Manufacturers
    • 2.5 Trend of Concentration Rate

    3 Global and Regional Prophylactic HIV Drug Market Status by Category

    • 3.1 Prophylactic HIV Drug Category Introduction
      • 3.1.1 Nucleoside or Nucleotide Reverse Transcriptase Inhibitors (NRTI)
      • 3.1.2 Integrase Inhibitor
    • 3.2 Global Prophylactic HIV Drug Market by Category
      • 3.2.1 Global Prophylactic HIV Drug Sales Volume by Category (2016-2021)
      • 3.2.2 Global Prophylactic HIV Drug Sales Value by Category (2016-2021)
      • 3.2.3 Global Prophylactic HIV Drug Price by Category (2016-2021)
    • 3.3 North America: by Category
    • 3.4 Europe: by Category
    • 3.5 Asia Pacific: by Category
    • 3.6 Central & South America: by Category
    • 3.7 Middle East & Africa: by Category

    4 Global and Regional Prophylactic HIV Drug Market Status by End User/Segment

    • 4.1 Prophylactic HIV Drug Segment by End User/Segment
      • 4.1.1 Hospital Pharmacy
      • 4.1.2 Retail Pharmacy
      • 4.1.3 Online Pharmacy
    • 4.2 Global Prophylactic HIV Drug Market by End User/Segment
      • 4.2.1 Global Prophylactic HIV Drug Sales Volume by End User/Segment (2016-2021)
      • 4.2.2 Global Prophylactic HIV Drug Sales Value by End User/Segment (2016-2021)
      • 4.2.3 Global Prophylactic HIV Drug Price by End User/Segment (2016-2021)
    • 4.3 North America: by End User/Segment
    • 4.4 Europe: by End User/Segment
    • 4.5 Asia Pacific: by End User/Segment
    • 4.6 Central & South America: by End User/Segment
    • 4.7 Middle East & Africa: by End User/Segment

    5 Global Prophylactic HIV Drug Market Status by Region

    • 5.1 Global Prophylactic HIV Drug Market by Region
      • 5.1.1 Global Prophylactic HIV Drug Sales Volume by Region
      • 5.1.2 Global Prophylactic HIV Drug Sales Value by Region
    • 5.2 North America Prophylactic HIV Drug Market Status
    • 5.3 Europe Prophylactic HIV Drug Market Status
    • 5.4 Asia Pacific Prophylactic HIV Drug Market Status
    • 5.5 Central & South America Prophylactic HIV Drug Market Status
    • 5.6 Middle East & Africa Prophylactic HIV Drug Market Status

    6 North America Prophylactic HIV Drug Market Status

    • 6.1 North America Prophylactic HIV Drug Market by Country
      • 6.1.1 North America Prophylactic HIV Drug Sales Volume by Country (2016-2021)
      • 6.1.2 North America Prophylactic HIV Drug Sales Value by Country (2016-2021)
    • 6.2 United States
    • 6.3 Canada
    • 6.4 Mexico

    7 Europe Prophylactic HIV Drug Market Status

    • 7.1 Europe Prophylactic HIV Drug Market by Country
      • 7.1.1 Europe Prophylactic HIV Drug Sales Volume by Country (2016-2021)
      • 7.1.2 Europe Prophylactic HIV Drug Sales Value by Country (2016-2021)
    • 7.2 Germany
    • 7.3 France
    • 7.4 UK
    • 7.5 Italy
    • 7.6 Russia
    • 7.7 Spain

    8 Asia Pacific Prophylactic HIV Drug Market Status

    • 8.1 Asia Pacific Prophylactic HIV Drug Market by Country
      • 8.1.1 Asia Pacific Prophylactic HIV Drug Sales Volume by Country (2016-2021)
      • 8.1.2 Asia Pacific Prophylactic HIV Drug Sales Value by Country (2016-2021)
    • 8.2 China
    • 8.3 Japan
    • 8.4 Korea
    • 8.5 Southeast Asia
    • 8.6 India
    • 8.7 Australasia

    9 Central & South America Prophylactic HIV Drug Market Status

    • 9.1 Central & South America Prophylactic HIV Drug Market by Country
      • 9.1.1 Central & South America Prophylactic HIV Drug Sales Volume by Country (2016-2021)
      • 9.1.2 Central & South America Prophylactic HIV Drug Sales Value by Country (2016-2021)
    • 9.2 Brazil
    • 9.3 Argentina
    • 9.4 Colombia

    10 Middle East & Africa Prophylactic HIV Drug Market Status

    • 10.1 Middle East & Africa Prophylactic HIV Drug Market by Country
      • 10.1.1 Middle East & Africa Prophylactic HIV Drug Sales Volume by Country (2016-2021)
      • 10.1.2 Middle East & Africa Prophylactic HIV Drug Sales Value by Country (2016-2021)
    • 10.2 Iran
    • 10.3 Israel
    • 10.4 Turkey
    • 10.5 South Africa
    • 10.8 Saudi Arabia

    11 Supply Chain and Manufacturing Cost Analysis

    • 11.1 Supply Chain Analysis
    • 11.2 Production Process Chart Analysis
    • 11.3 Raw Materials and Key Suppliers Analysis
      • 11.3.1 Raw Materials Introduction
      • 11.3.2 Raw Materials Key Suppliers List
    • 11.4 Prophylactic HIV Drug Manufacturing Cost Analysis
    • 11.5 Prophylactic HIV Drug Sales Channel and Distributors Analysis
      • 11.5.1 Prophylactic HIV Drug Sales Channel
      • 11.5.2 Prophylactic HIV Drug Distributors
    • 11.6 Prophylactic HIV Drug Downstream Major Buyers

    12 Global Prophylactic HIV Drug Market Forecast by Category and by End User/Segment

    • 12.1 Global Prophylactic HIV Drug Sales Volume and Sales Value Forecast (2022-2027)
    • 12.2 Global Prophylactic HIV Drug Forecast by Category
      • 12.2.1 Global Prophylactic HIV Drug Sales Volume Forecast by Category
      • 12.2.2 Global Prophylactic HIV Drug Sales Value Forecast by Category
      • 12.2.3 Global Prophylactic HIV Drug Price Forecast by Category
    • 12.3 Global Prophylactic HIV Drug Forecast by End User/Segment
      • 12.3.1 Global Prophylactic HIV Drug Sales Volume Forecast by End User/Segment
      • 12.3.2 Global Prophylactic HIV Drug Sales Value Forecast by End User/Segment
      • 12.3.3 Global Prophylactic HIV Drug Price Forecast by End User/Segment

    13 Global Prophylactic HIV Drug Market Forecast by Region/Country

    • 13.1 Global Prophylactic HIV Drug Market Forecast by Region (2022-2027)
      • 13.1.1 Global Prophylactic HIV Drug Sales Volume Forecast by Region (2022-2027)
      • 13.1.2 Global Prophylactic HIV Drug Sales Value Forecast by Region (2022-2027)
    • 13.2 North America Market Forecast
    • 13.3 Europe Market Forecast
    • 13.4 Asia Pacific Market Forecast
    • 13.5 Central & South America Market Forecast
    • 13.6 Middle East & Africa Market Forecast

    14 Key Participants Company Information

    • 14.1 Roche
      • 14.1.1 Company Information
      • 14.1.2 Prophylactic HIV Drug Product Introduction
      • 14.1.3 Roche Prophylactic HIV Drug Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.1.4 SWOT Analysis
    • 14.2 Mylan
      • 14.2.1 Company Information
      • 14.2.2 Prophylactic HIV Drug Product Introduction
      • 14.2.3 Mylan Prophylactic HIV Drug Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.2.4 SWOT Analysis
    • 14.3 Merck
      • 14.3.1 Company Information
      • 14.3.2 Prophylactic HIV Drug Product Introduction
      • 14.3.3 Merck Prophylactic HIV Drug Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.3.4 SWOT Analysis
    • 14.4 Gilead Sciences
      • 14.4.1 Company Information
      • 14.4.2 Prophylactic HIV Drug Product Introduction
      • 14.4.3 Gilead Sciences Prophylactic HIV Drug Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.4.4 SWOT Analysis
    • 14.5 Cipla
      • 14.5.1 Company Information
      • 14.5.2 Prophylactic HIV Drug Product Introduction
      • 14.5.3 Cipla Prophylactic HIV Drug Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.5.4 SWOT Analysis
    • 14.6 Bristol-Myers Squibb
      • 14.6.1 Company Information
      • 14.6.2 Prophylactic HIV Drug Product Introduction
      • 14.6.3 Bristol-Myers Squibb Prophylactic HIV Drug Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
      • 14.6.4 SWOT Analysis

    ...

      15 Conclusion

        16 Methodology

        Covid-19 has impacted the supply and demand status for many industries along the supply chain. In this report a comprehensive analysis of current global Prophylactic HIV Drug market in terms of demand and supply environment is provided, as well as price trend currently and in the next few years. Global leading players are profiled with their revenue, market share, profit margin, major product portfolio and SWOT analysis. From industry perspective this report analyses supply chain, including process chart introduction, upstream key raw material and cost analysis, distributor and downstream buyer analysis. This report also includes global and regional market size and forecast, major product development trend and typical downstream segment scenario, under the context of market drivers and inhibitors analysis. According to this survey, the global Prophylactic HIV Drug market is estimated to have reached $ xx million in 2020, and projected to grow at a CAGR of xx% to $ xx million in 2027.

        Segmented by Category
        Nucleoside or Nucleotide Reverse Transcriptase Inhibitors (NRTI)
        Integrase Inhibitor

        Segmented by End User/Segment
        Hospital Pharmacy
        Retail Pharmacy
        Online Pharmacy

        Segmented by Country
        North America
        United States
        Canada
        Mexico
        Europe
        Germany
        France
        UK
        Italy
        Russia
        Spain
        Asia Pacific
        China
        Japan
        Korea
        Southeast Asia
        India
        Australasia
        Central & South America
        Brazil
        Argentina
        Colombia
        Middle East & Africa
        Iran
        Israel
        Turkey
        South Africa
        Saudi Arabia

        Key manufacturers included in this survey
        Roche
        Mylan
        Merck
        Gilead Sciences
        Cipla
        Bristol-Myers Squibb


        Summary:
        Get latest Market Research Reports on Prophylactic HIV Drug. Industry analysis & Market Report on Prophylactic HIV Drug is a syndicated market report, published as Dynamics in Post-pandemic Global Prophylactic HIV Drug Industry: Supply and Demand, Markets and Prices 2021-2027. It is complete Research Study and Industry Analysis of Prophylactic HIV Drug market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

        Last updated on

        REPORT YOU MIGHT BE INTERESTED

        Purchase this Report

        $2,980.00
        $4,470.00
        $5,960.00
        2,154.54
        3,231.81
        4,309.08
        2,506.18
        3,759.27
        5,012.36
        328,396.00
        492,594.00
        656,792.00
        220,818.00
        331,227.00
        441,636.00
        Credit card Logo

        Related Reports


        Reason to Buy

        Request for Sample of this report